Skip to content

ZEVRA THERAPEUTICS, INC.

ZVRA · XNAS

CIK 1434647fmd_0DNP2N4QECV88Z0WYZVHT0JHV4Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2013 to Sep 30, 2026, 52 periods

Latest annual · FY2025

Millions
Total revenues
106
Gross profit
25
Operating income
(63)
Net income
83
Free cash flow
(2)

Latest quarter · Q3 FY2026

Millions
Total revenues
38
Operating income
12
Net income
19
Free cash flow
10
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2022 to FY2025
+118.8%
Revenue, 5 yearsFY2020 to FY2025
+51.6%
Net income, 5 yearsFY2020 to FY2025
n/m

ZEVRA THERAPEUTICS, INC. (ZVRA) financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2025FY2024ChangeSource
Revenue$106.5 million$23.6 million+350.9%10-K 2026-03-09 · proof
Operating income-$62.9 million-$87 million10-K 2026-03-09 · proof
Net income$83.2 million-$105.5 million10-K 2026-03-09 · proof
Cash from operating activities-$1.6 million-$69.7 million10-K 2026-03-09 · proof
Free cash flow-$2.4 million-$69.7 million10-K 2026-03-09 · proof
Total assets$284.7 million$178.1 million+59.8%10-K 2026-03-09 · proof
Total liabilities$130.1 million$138.5 million-6.1%10-K 2026-03-09 · proof
Cash and cash equivalents$62.4 million$33.8 million+84.7%10-K 2026-03-09 · proof
What was ZEVRA THERAPEUTICS, INC. (ZVRA)'s revenue in fiscal 2025?
ZEVRA THERAPEUTICS, INC. (ZVRA) reported revenue of $106.5 million for fiscal 2025 (the year ended Dec 31, 2025), against $23.6 million the year before (+350.9%). Source: the 10-K filed with the SEC on Mar 9, 2026. SEC
What was ZEVRA THERAPEUTICS, INC. (ZVRA)'s operating income in fiscal 2025?
ZEVRA THERAPEUTICS, INC. (ZVRA) reported operating income of -$62.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$87 million the year before. Source: the 10-K filed with the SEC on Mar 9, 2026. SEC
What was ZEVRA THERAPEUTICS, INC. (ZVRA)'s net income in fiscal 2025?
ZEVRA THERAPEUTICS, INC. (ZVRA) reported net income of $83.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$105.5 million the year before. Source: the 10-K filed with the SEC on Mar 9, 2026. SEC
What was ZEVRA THERAPEUTICS, INC. (ZVRA)'s cash from operating activities in fiscal 2025?
ZEVRA THERAPEUTICS, INC. (ZVRA) reported cash from operating activities of -$1.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$69.7 million the year before. Source: the 10-K filed with the SEC on Mar 9, 2026. SEC
What was ZEVRA THERAPEUTICS, INC. (ZVRA)'s free cash flow in fiscal 2025?
ZEVRA THERAPEUTICS, INC. (ZVRA) reported free cash flow of -$2.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$69.7 million the year before. Source: the 10-K filed with the SEC on Mar 9, 2026. SEC
What are ZEVRA THERAPEUTICS, INC. (ZVRA)'s total assets?
As of Dec 31, 2025, ZEVRA THERAPEUTICS, INC. (ZVRA) reported total assets of $284.7 million, against $178.1 million a year earlier (+59.8%). Source: the 10-K filed with the SEC on Mar 9, 2026. SEC
What are ZEVRA THERAPEUTICS, INC. (ZVRA)'s total liabilities?
As of Dec 31, 2025, ZEVRA THERAPEUTICS, INC. (ZVRA) reported total liabilities of $130.1 million, against $138.5 million a year earlier (-6.1%). Source: the 10-K filed with the SEC on Mar 9, 2026. SEC
What are ZEVRA THERAPEUTICS, INC. (ZVRA)'s cash and cash equivalents?
As of Dec 31, 2025, ZEVRA THERAPEUTICS, INC. (ZVRA) reported cash and cash equivalents of $62.4 million, against $33.8 million a year earlier (+84.7%). Source: the 10-K filed with the SEC on Mar 9, 2026. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:ZVRA&period_type=annual&limit=5"

Information only, not investment advice.